Thirty-six patients with a mean age of 64.56
years were collected. Endometrioid carcinoma was diagnosed in 77.8%, serous
carcinoma in 11.1%, carcinosarcoma in 5.6% and clear cell carcinoma in 5.6%.
VILI was present in 33.3% and 58.3% had a depth of more than 50% of the
myometrium. 22.2% were grade 1, 41.67% G2 and 36.11% G3 or poorly
differentiated. 86.11% were classified as FIGO I-II. TEN was performed over the
pelvis in 20 patients (56%).
The diameters of the applicators used were 2.5,
3 and 3.5 in 8%, 42% and 50% respectively. The active length treated was 2.5 cm
in 19% and 3 cm in 81%.
25 patients (69.4%) presented some type of
acute toxicity: rectal toxicity 13, urinary toxicity 12 and on vaginal mucosa
13, with no G3 toxicity observed. 8 patients (22.2%) presented some type of
late toxicity: urinary toxicity 1, rectal toxicity 4 and on vaginal mucosa 6,
none of them G3.
A statistically significant association was
found between TEN and acute rectal toxicity (p= 0.008).
With a follow-up of 67.48 months 9 patients
have relapsed (25%). 7 patients at a distance, 1 through pelvic adenopathies
and 1 in the lower third of the vagina (not irradiated). 6 patients have died,
4 of them due to their oncologic disease (11.11%).
A statistically significant association was
found between myometrial invasion greater than 50% and recurrence (p= 0.032) as
well as exitus with oncologic history (p=0.038), histology type 1-2 (p=0.033)
and FIGO stage (p= 0.010).